Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alphamab Oncology ( (HK:9966) ) has issued an announcement.
Alphamab Oncology announced that its Investigational New Drug (IND) application for JSKN027, a first-in-class PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC), has been officially accepted by China’s Center for Drug Evaluation (CDE). This milestone positions JSKN027 as a potentially groundbreaking treatment for advanced malignant solid tumors, offering a robust three-fold synergistic mechanism that emphasizes targeted chemo, immune checkpoint disruption, and anti-angiogenesis effects. Its acceptance reflects the company’s innovative approach and reinforces its standing in the competitive oncology space, potentially providing significant benefits to patients and stakeholders.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company based in China, specializing in advanced oncology therapies. The company operates with a proprietary technology platform focusing on antibody-drug conjugates (ADCs), bispecific antibodies, and multi-functional protein engineering, with a diversified pipeline including approved and late-stage clinical trial products.
Average Trading Volume: 2,923,078
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.05B
For an in-depth examination of 9966 stock, go to TipRanks’ Overview page.